Atrium Injection

Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.


Atracurium is used for endotracheal intubation, facilitate mechanical ventilation in intensive care, muscle relaxant in general anaesthesia.

Atrium is also used to associated treatment for these conditions: Neuromuscular blocking therapy, Facilitation of small bowel intubation therapy

Trade Name Atrium
Generic Atracurium besylate
Other Names Atracurium besilate, Atracurium besylate, Atracurium dibesylate, Besilate d'atracurium, Besilato de atracurio
Weight 10mg/ml
Type Injection
Formula C65H82N2O18S2
Weight Average: 1243.49
Monoisotopic: 1242.500406156
Therapeutic Class Non depolarizing muscle relaxants
Manufacturer Chemist Laboratories Limited
Available Country Bangladesh
Last Updated: June 23, 2021 at 11:16 am


Atrium dosage

Adult and Child (>1 month): Initially, 300-600 mcg/kg as bolus IV, with subsequent doses of 100-200 mcg/kg by IV every 15-25 min or 5-10 mcg/kg/min by infusion in prolonged procedures. Higher infusion rate may be used in patients undergoing controlled ventilation in intensive care.

Side Effects

Skin flush, erythema, pruritus, urticaria, wheezing, increased bronchial secretions, bronchospasm, cyanosis, angioedema, CV effects (e.g. bradycardia); wheals and erythema at inj site. Potentially Fatal: Anaphylaxis.


Patient with CV disease, burn injury, asthma; conditions which may antagonise neuromuscular blockade (e.g. resp alkalosis, hypercalcaemia, demyelinating lesions, peripheral neuropathies, denervation, muscle trauma); conditions which may potentiate neuromuscular blockade (e.g. electrolyte abnormalities, neuromuscular diseases, metabolic acidosis, resp acidosis, Eaton-Lambert syndrome, myasthenia gravis). Pregnancy and lactation.


Enhanced neuromuscular blocking effect w/ general anaesth (e.g. enflurane, isoflurane, halothane), certain antibiotics (e.g. aminoglycosides, polymyxins), lithium, Mg salts, procainamide, quinidine.

Food Interaction

No interactions found.

Half Life

The elimination half-life is approximately 20 minutes.

Pregnancy & Breastfeeding use

Pregnancy Category C: Teratogenic Effects. Atrium has been shown to be potentially teratogenic in rabbits when given in doses up to approximately one-half the human dose. There are no adequate and well-controlled studies in pregnant women. Atracurium should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


Atracurium is contraindicated in patients known to be hypersensitive to atracurium, cisatracurium or benzenesulfonic acid. In common with all the other neuromuscular blocking agents, atracurium besilate paralyses the respiratory muscles as well as other skeletal muscles but has no effect on consciousness.

Acute Overdose

Stimulation of histamine release, CV effects especiall hypotension

Storage Condition

Store between 2-8° C. Do not freeze.

Atrium contains Atracurium besylate see full prescribing information from innovator Monograph